Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ctla4 aptamer inhibitor
- Development stage
- Preclinical
- Lead developer
- Shanghai Microbio Technology
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ctla4 aptamer inhibitor is a preclinical-stage nucleic acid aptamer candidate being developed by Shanghai Microbio Technology. Discovered using the company's high-throughput nucleic acid aptamer screening platform, the candidate is designed to physically bind to and inhibit cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling. By blocking the CTLA-4 checkpoint pathway, the aptamer aims to enhance T-cell activation and proliferation, serving as an immuno-oncology therapeutic for the treatment of cancer.
- Other names
- CTLA-4 aptamer inhibitorCTLA4 aptamer inhibitorCTLA 4 aptamer inhibitorCTLA4 aptamerCTLA-4 aptamerCTLA 4 aptamerCTLA4核酸适配体抑制剂CTLA4适体药物
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on ctla4 aptamer inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ctla4 aptamer inhibitor.